TL;DR
A real-world study of a brain health service in Monza, Italy, found that modifiable dementia risk factors were common among people with subjective cognitive decline, even though standard cognitive testing can remain normal. Among participants with available blood tests, elevated p-Tau217 was linked to early signs of neurodegeneration; about 60% of those who received results said they felt more motivated to make lifestyle changes.
A study of 186 attendees at a brain health service in Monza, Italy, found that people who reported memory or thinking changes despite normal performance on standard cognitive tests often had modifiable dementia risk factors. In the group with subjective cognitive decline, higher blood levels of the Alzheimer’s-related biomarker p-Tau217 were also linked to early signs of neurodegeneration, the researchers reported in Neurological Sciences.
The study included 132 people with subjective cognitive decline (SCD), a term for noticing changes in memory or other thinking abilities while continuing to perform normally on standard cognitive tests. Among SCD participants with available blood results, researchers classified people as biomarker-positive or biomarker-negative using a p-Tau217 threshold of 0.15 picograms per milliliter. The study reported signs of neurodegeneration among those at or above that threshold. This association does not show that the biomarker caused the changes or that every person with SCD will develop dementia.
At a second visit, participants were told their p-Tau217 and APOE genotype results and given an individualized estimate of dementia risk. The estimate combined a relative-risk measure based on Lancet Commission risk factors with baseline risk calculated using the Brookmeyer method and Italian mortality data. Researchers recommended preventive measures and used online questionnaires a week later to assess participants’ response to the disclosure.
About 60% of participants who received results reported greater motivation to make lifestyle changes, according to the report. That finding reflects participants’ self-reported motivation after receiving information; it does not show that they made the changes or that their dementia risk fell. The study was based on people attending one service, and its authors described comparisons among the service’s different clinical groups as exploratory, in part because of small group sizes.
Why Normal Test Scores May Not Settle Risk
The findings highlight a gap between subjective concerns and performance on standard cognitive tests. People may notice changes before a test identifies impairment, but SCD is not a diagnosis of dementia and can have multiple causes. The study suggests that a preventive assessment may help clinicians consider health and lifestyle risks alongside test scores, rather than treating a normal score as a complete account of a person’s concerns.
Biomarker disclosure also has practical and ethical implications. The reported increase in motivation suggests that carefully explained risk information may encourage some people to consider prevention. But a blood result and a risk estimate can be difficult to interpret, and this study did not establish whether disclosure leads to sustained behavior changes, improves health outcomes, or is appropriate for everyone. Its findings are evidence about one service’s experience, not proof that broad biomarker screening benefits the public.
As an affiliate, we earn on qualifying purchases.
How Brain Health Services Assess Concerns
Subjective cognitive decline is heterogeneous: it may precede measurable impairment for some people, while other cases may relate to non-neurodegenerative causes. The report cites prior research suggesting that up to one-third of people with SCD may have preclinical Alzheimer’s disease in some settings, but that estimate varies by setting and does not describe every person with SCD.
The Monza service is part of a model designed to focus on risk assessment and prevention, rather than diagnosis and treatment alone. Its assessment can include cognitive screening, blood biomarkers such as p-Tau217 and GFAP, APOE genotyping, and brain imaging. People found to have mild cognitive impairment can be referred to a memory clinic. The authors place this approach against differing professional guidance: the Alzheimer’s Association workgroup advises against diagnostic biomarker testing in cognitively unimpaired people outside observational or treatment research, while the International Working Group allows non-diagnostic testing pathways for risk estimation and reduction in people with SCD.
“About 60% of participants who underwent disclosure reported greater motivation for lifestyle changes.”
— The study authors, as summarized by News-Medical
As an affiliate, we earn on qualifying purchases.
Limits of the Monza Findings
The study examined one brain health service and included a relatively small number of attendees, so its results may not represent people with memory concerns elsewhere. The report does not establish how many SCD participants had elevated p-Tau217, whether biomarker-positive participants later developed measurable impairment, or how the findings compare with a group that did not receive results.
It is also unclear whether participants’ reported motivation led to lasting lifestyle changes or altered their health outcomes. The findings do not settle whether Alzheimer’s disease should be diagnosed at the SCD stage, how reliably this test performs across different populations, or how best to communicate uncertain future risk. A biomarker result or risk estimate should not be read as a prediction that a particular person will develop dementia.
memory test for early dementia detection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Follow-Up on Risk Disclosure
The next questions are whether people who receive this type of disclosure make sustained changes and whether those changes affect measured health or cognitive outcomes. Longer follow-up and studies across multiple services would help determine whether the Monza results apply beyond this setting and how useful the assessment is in routine care.
For now, the report describes an emerging prevention model rather than a new standard of diagnosis. Decisions about biomarker testing and interpretation remain dependent on clinical guidance and individual circumstances. People concerned about memory changes can discuss them with a qualified health professional, who can assess possible causes and whether further evaluation is appropriate.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is subjective cognitive decline?
Subjective cognitive decline means a person notices changes in memory or thinking but continues to perform normally on standard cognitive tests. It has varied causes and does not, by itself, mean that the person has dementia.
What did the Monza study find about p-Tau217?
Among SCD participants with available blood results, levels at or above the study’s 0.15 pg/mL threshold were linked to signs of neurodegeneration. The finding is an association, not proof that a person will develop Alzheimer’s disease.
Did receiving biomarker results change participants’ behavior?
About 60% reported greater motivation to make lifestyle changes after results and risk estimates were shared. The study did not establish whether they followed through or whether any changes reduced dementia risk.
Does a positive p-Tau217 result diagnose Alzheimer’s disease?
Not on the basis of this study. Guidance described in the report differs, and the International Working Group generally treats biomarker-positive, cognitively unimpaired people as being at risk, rather than as having Alzheimer’s disease. Testing and results require clinical interpretation.
Source: rss
